- 1Department of Internal Medicine, Uijeongbu Eulji Medical Center, Eulji University, Gyeonggi-Do, Republic of Korea
- 2Clinical Trial Center, Dongguk University Ilsan Hospital, Goyang, Republic of Korea
- 3Research Center for Chronic Disease and Environmental Medicine, Dongguk University College of Medicine, Gyeongju, Republic of Korea
- 4Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, Republic of Korea
- 5Division of Nephrology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea
- 6Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
- 7Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea
- 8Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Republic of Korea
- 9Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Republic of Korea
- 10Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
- 11Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
- 12Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Republic of Korea
Introduction: Patients with acute kidney injury (AKI) receiving renal replacement therapy constitute the subgroup of AKI with the highest risk of mortality. Despite recent promising findings on the neutrophil-to-lymphocyte ratio (NLR) in AKI, studies have not yet addressed the clinical implication of the NLR in this population. Therefore, we aimed to examine the prognostic value of NLR in critically ill patients requiring continuous renal replacement therapy (CRRT), especially focusing on temporal changes in NLR.
Methods: We enrolled 1,494 patients with AKI who received CRRT in five university hospitals in Korea between 2006 and 2021. NLR fold changes were calculated as the NLR on each day divided by the NLR value on the first day. We performed a multivariable Cox proportional hazard analysis to assess the association between the NLR fold change and 30-day mortality.
Results: The NLR on day 1 did not differ between survivors and non-survivors; however, the NLR fold change on day 5 was significantly different. The highest quartile of NLR fold change during the first 5 days after CRRT initiation showed a significantly increased risk of death (hazard ratio [HR], 1.65; 95% confidence intervals (CI), 1.27–2.15) compared to the lowest quartile. NLR fold change as a continuous variable was an independent predictor of 30-day mortality (HR, 1.14; 95% CI, 1.05–1.23).
Conclusion: In this study, we demonstrated an independent association between changes in NLR and mortality during the initial phase of CRRT in AKI patients receiving CRRT. Our findings provide evidence for the predictive role of changes in the NLR in this high-risk subgroup of AKI.
Introduction
Acute kidney injury (AKI) affects approximately 13.3 million people worldwide each year and is strongly associated with serious outcomes such as death, cardiovascular disease, and chronic kidney disease (CKD) progression (1–3). AKI-related mortality was estimated to be 23.9% in a pooled meta-analysis (4). Critically ill patients with AKI are at an even higher risk of death. In intensive care settings, the mortality rate of AKI patients requiring renal replacement therapy (RRT) is reported to reach up to 60% (5, 6). In recent decades, an increasing amount of resources, including continuous renal replacement therapy (CRRT), have been utilized to treat patients with AKI (7). Nonetheless, mortality in critically ill patients with AKI remains high, as shown in recent trials (8, 9). Several biomarkers, such as TIMP-2 × IGFBP7, TNF receptor-I, IL-6, and IL-8, have been investigated and have been shown to be associated with mortality in AKI patients (10, 11). However, such biomarkers have not been validated and standardized and are still far from routine clinical use.
Recently, the neutrophil-to-lymphocyte ratio (NLR) has been highlighted as a potential prognostic biomarker for various diseases. A high NLR has been associated with an increased mortality risk in cardiovascular diseases (12, 13), infections (14), and malignant tumors (15, 16). Neutrophils are representative cells of innate immunity, whereas lymphocytes are the core of adaptive immunity. Therefore, NLR, a proportional measure of one type of white blood cells over the other, might serve as a useful marker of systemic inflammation. Also, this measure is readily available through common laboratory tests.
The NLR has also attracted research interest in AKI. Neutrophils and monocytes mediate the acute phase of the first 24–48 h of AKI (17). Lymphocyte infiltration and production of associated cytokines are major factors in AKI 48 h after ischemic injury (18). This may be the underlying pathophysiology of AKI development, which may affect changes in the NLR. However, most studies on NLR have mainly focused on the diagnostic value of NLR for AKI (19), and data on its association with mortality in patients with AKI are inconsistent (20, 21). Moreover, patients included in related studies were mostly in the early stages of AKI, most of whom did not receive RRT (22, 23). Individuals with severe AKI requiring RRT often suffer from multiorgan failure and severe systemic inflammation, which leads to high mortality. Thus, there is an unmet need for potential biomarkers in this population. The clinical implications of NLR in patients receiving CRRT have not been extensively assessed. Furthermore, many previous studies have utilized NLR values at a single time point, and the effect of dynamic changes in NLR has rarely been studied in AKI. Therefore, we aimed to evaluate the prognostic value and dynamic nature of the NLR in patients with severe AKI requiring CRRT using data from a multicenter retrospective cohort.
Methods
Study design and population
We retrospectively enrolled patients aged ≥18 years who received CRRT for ≥24 h for AKI at five university hospitals (Dongguk University Ilsan Hospital, Seoul National University Hospital, Kyungpook National University Chilgok Hospital, Eunpyeong St. Mary’s Hospital, and Inha University Hospital) in Korea. We excluded patients who (1) were diagnosed with end-stage kidney disease or terminal-stage cancer and (2) had missing NLR or covariates. Demographic and biochemical data at baseline were collected from electronic health records (EHR) of each hospital, including the date of admission and discharge, CRRT initiation and termination date, sex, age, cause of AKI (sepsis or non-sepsis), body mass index (BMI), Charlson comorbidity index (CCI), C-reactive protein, hemoglobin, heart rate, respiratory rate, potassium, sodium, blood urea nitrogen (BUN), use of mechanical ventilation, acute physiology and chronic health evaluation (APACHE II) score, and sequential organ failure assessment (SOFA) score (24, 25). The main outcome was 30-day mortality based on EHR. This study was approved by the Institutional Review Boards of Dongguk University Ilsan Hospital (DUIH 2022-06-019-002), Seoul National University Hospital (H-2212-142-1,389), Kyungpook National University Chilgok Hospital (KNUCH 2022–09-020), Eunpyeong St. Mary’s Hospital (PC21RIDI0111), and Inha University Hospital (2022-08-046) and informed consent was waived due to the retrospective nature of the study.
NLR and NLR fold change
The NLR was calculated as the ratio of neutrophil count to lymphocyte count obtained from the differential count over 5 days after CRRT initiation. The NLR fold change was defined as the ratio of NLRs measured on a given day after CRRT initiation and the CRRT initiation date. For example, the NLR fold change on day 2 was the NLR on day 2 after CRRT initiation divided by the NLR on day 1 (NLR day 2/NLR day 1).
Statistical analyses
We conducted simple and multiple logistic regression to identify the odds ratios of the NLR fold change on 30-day mortality according to different durations after CRRT initiation using c-statistics. Model 1 was a crude model, and Model 2 was additionally adjusted for sex, age, BMI, CCI, sepsis, hypertension, diabetes, and baseline NLR. Model 3 was further adjusted for C-reactive protein, systolic blood pressure, diastolic blood pressure, creatinine, hemoglobin, heart rate, respiratory rate, potassium, sodium, BUN, SOFA score, mechanical ventilation, and CRRT duration. After selecting the fold change on day 5 after CRRT initiation, we estimated the survival probability between 30-day mortality and quartiles of fold change on day 5 in the Kaplan–Meier plot. In addition, a Cox proportional hazards model was used to investigate the association between 30-day mortality and fold change on day 5. The fold change on day 5 was applied as a continuous and categorical variable in Models 1, 2, and 3. In addition, hazard ratios (HR) and 95% confidence intervals (CI) per 1-fold increase are presented in the continuous model, and the HRs of each quartile compared to the lowest quartile were shown in the categorical model. To assess the susceptible subgroups, stratified analyses were conducted for AKI cause (sepsis, non-sepsis), sex, age (<65 years, ≥65 years), and days from admission to CRRT initiation (<3 days and ≥3 days). All statistical analyses were performed using R version 4.2.1 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics
A total of 1,494 patients were included in the main analysis. The mean age was 65.7 years, and 61.8% of the patients were men (Table 1). Hypertension and diabetes mellitus were present in 35.5 and 36.5% of the patients, respectively. The mean duration of CRRT was 9.0 days; 38.8% of the patients had sepsis, and 72.6% were on mechanical ventilation. The mean baseline NLR was 21.9, which is comparable to the NLR value ranged from 17 to 23 in critical stress and inflammation (26). The mean baseline SOFA and APACHE II scores were 11.5 and 25.4, respectively. The baseline characteristics of the quartile groups of participants according to the NLR fold change on day 5 are shown in Table 1. Age, sex, and CCI did not differ among NLR fold-change quartiles. The baseline NLR value was lowest in the fourth quartile of the NLR fold change. The proportion of mechanical ventilation, APACHE II, and SOFA scores were significantly higher in the upper quartiles of NLR fold change on day 5, while no differences were found between the quartiles of baseline NLR value (Supplementary Table S1).
Dynamic nature and fold change of the NLR
Dynamic changes in neutrophils and lymphocytes after CRRT initiation are shown in Figure 1. Overall changes in neutrophil and lymphocyte counts were more obvious in non-survivors than in survivors. The non-survivor group showed increasing neutrophil counts and decreasing lymphocyte counts during the observation period. In terms of the NLR fold change, NLR values in the survivor group started to decrease on day 4 and returned to almost baseline levels on day 5, but this was not observed in the case of non-survivors. The NLR fold change kept increasing in the non-survivor group over the treatment period. The NLR fold change was not different between the survivor and non-survivor groups on day 1, but a significant difference was found on day 5 (p = 0.001). When the relationship between neutrophil and lymphocyte counts was plotted and fitted to a linear model according to 30-day mortality, a significant interaction with mortality was found on day 5 but not on day 1 (Figure 2).
Figure 1. Dynamic changes of neutrophil (A), lymphocyte (B), neutrophil-to-lymphocyte ratio (NLR) (C), and fold changes of NLR (D) during the first 5 days after CRRT initiation.
Figure 2. The relationship between neutrophil and lymphocyte counts for survivors and non-survivors (A) at baseline, (B) on day 5 after CRRT initiation.
Association between NLR fold change and 30-day mortality
The 30-day mortality rate was 37.9%, which is comparable to that of another study performed on the Korean population (27). The mortality rate was lowest in the first quartile of NLR fold change (31.6%) and highest in the fourth quartile (44.9%). The odd ratios of NLR fold change for different durations after CRRT initiation for 30-day mortality are given in Supplementary Table S2. The NLR fold change was statistically significant in the crude model (Model 1) on day 4 (OR, 1.08; 95% CI, 1.01–1.15) and day 5 (OR, 1.22; 95% CI, 1.10–1.35), but only on day 5 (OR, 1.23; 95% CI, 1.09–1.39) in the fully adjusted model (Model 3). In addition, c-statistic, which indicates the discriminative ability based on sensitivity and specificity, was the highest on day 5. The Kaplan–Meier survival curve of NLR fold change on day 5 for 30-day mortality revealed a significant difference between the NLR fold-change quartiles (Figure 3). The fourth quartile of NLR fold change showed the lowest survival, and the first quartile showed the best survival. In Cox proportional hazard regression analysis, the NLR fold change on day 5 was significantly associated with 30-day mortality (Table 2). The HRs (95% CI) of the second, third, and fourth quartiles were 1.33 (1.02–1.72), 1.42 (1.10–1.85), and 1.65 (1.27–2.15), respectively, with a statistically significant linear trend (p for trend <0.001). The HR for each 1-fold increase in NLR fold change was 1.14 (95% CI, 1.05–1.23) in the fully adjusted model.
Figure 3. Kaplan–Meier plot between mortality and quartiles of fold change on day 5 after CRRT initiation.
Table 2. Hazard ratio and 95% confidence interval on 30-day mortality associated with the fold change in NLR on day 5 after CRRT initiation.
Subgroup analysis
We conducted subgroup analyses by stratifying patients according to AKI cause, sex, age, and the number of days from CRRT initiation (Figure 4). The association between NLR fold change on day 5 and 30-day mortality was statistically significant, particularly in individuals with septic-AKI, male sex, age ≥65 years, and duration between admission and CRRT initiation <3 days. However, no significant modifying effect was identified, except for age (p for interaction = 0.04).
Figure 4. Subgroup analysis between 30-day mortality and fold change on day 5 after CRRT initiation by AKI cause, sex, age, and days from admission to CRRT initiation.
Discussion
Patients with AKI receiving CRRT are a high-risk group and show substantially higher mortality. In this study, we elucidated the dynamic characteristics of NLR during CRRT and showed the associations between changes in NLR and mortality. We identified that changes in NLR during the initial phase after CRRT initiation were markedly different between survivors and non-survivors. In particular, the NLR fold change during the first 5 days after CRRT initiation was significantly associated with 30-day mortality. These results were consistent after adjusting for multiple covariates, including baseline NLR values, showing the importance of continuous monitoring of changes in NLR.
The NLR can be easily calculated using a simple ratio of two immune cell counts. Nonetheless, NLR potentially implicates an immune-inflammatory response in various pathological conditions (26). AKI has a multifactorial pathophysiology, among which inflammation plays a pivotal role in the development of AKI (28, 29). This suggests that the NLR can be used as a useful marker of AKI progression and mortality. In the field of AKI, compared with studies on the diagnostic value of NLR, relatively fewer studies have been conducted on the prognostic value of NLR (19). Previous studies have mainly investigated mortality as a secondary outcome, and none have specifically evaluated patients receiving RRT. A study by Fan et al. using the Medical Information Mart for Intensive Care Database III showed that NLR measured within the first 24 h after admission was independently associated with 30-day and in-hospital mortality in critically ill patients (30). In this study, only 8.9% of the patients received RRT, and 40% had stage 1 and 2 AKI. A retrospective multicenter study in Taiwan also revealed a J-shaped association between NLR near AKI identification and AKI progression, RRT, and in-hospital mortality (22). Despite the positive findings, patients with stage 3 AKI were excluded due to the study design. In AKI patients undergoing RRT, the association between NLR and mortality and its clinical significance have not yet been elucidated. In our study, all participants were critically ill patients with hemodynamic instability who started CRRT at baseline. We revealed the potential predictive value of the NLR in this population. Given the lack of accurate and valid predictive markers, our findings provide valuable insights into NLR in the high-risk population.
Notably, some other studies with similar designs failed to reveal the association of NLR with mortality (20, 21). The causes of this discrepancy could have resulted from the use of baseline NLR only. Still, studies on AKI have focused on the baseline NLR without considering changes in NLR during the clinical course. However, immunologic responses in critically ill patients vary dynamically and immediately, and various immune cells and cytokines are involved in organ failure in real-time. The NLR reflects these highly dynamic immune responses. Indeed, NLR is an earlier marker than the usual inflammatory markers, such as white blood cell count and C-reactive protein levels (31). Recent studies have emphasized the serial assessment of NLR. Riche et al. revealed that, in addition to the baseline NLR, NLR changes for the first 5 days were significantly associated with ICU mortality in patients with septic shock (32). In patients hospitalized with pneumonia, the baseline NLR did not differ between survivors and non-survivors, but incremental changes in the NLR from day 1 to 4 accurately predicted 30-day mortality (33). In our study, NLR at CRRT initiation did not differ between survivors and non-survivors, but a close association was found between mortality and fold changes in NLR rather than the baseline NLR. Similar to the studies evaluating changes in NLR, our observation period for tracking NLR was 5 days.
A high NLR is attributed to neutrophilia and lymphopenia, which are caused by the biological processes of two immune cells in the opposite direction. The currently known mechanisms of neutrophilia and lymphopenia include demargination and margination to the vascular endothelium, delayed and accelerated apoptosis, mobilization and demobilization from the bone marrow, and distribution in blood circulation and redistribution in lymphatic tissue (26). In our subgroup analysis, the NLR was strongly associated with 30-day mortality in sepsis-associated AKI. Sepsis has been the most studied condition in relation to NLR and is also the most common etiology of severe AKI (7). Neutrophils are regarded as key drivers of immune dysregulation in sepsis (34). Increased lymphocyte apoptosis is observed in patients with sepsis, which is closely related to mortality (35). Lymphopenia has also been suggested as a single strong predictor of mortality, distinct from the neutrophil count (36). We found that both neutrophil and lymphocyte counts showed different trends during the first few days after CRRT initiation. The relative changes in lymphocytes were greater than those in neutrophils; thus, the difference in NLR appears to be more driven by a decrease in lymphocytes in non-survivors. In addition, subgroup analysis stratified by age revealed the interaction between age and NLR changes. This finding might have been due to immune dysfunction associated with immunosenescence in the elderly. Indeed, in patients with sepsis, non-survivors aged ≥65 years develop markedly prolonged and profound lymphocytopenia, contributing to delayed death (37).
The potential role of CRRT in the regulation of immune homeostasis remains largely unknown. We cannot assess the effect of CRRT on immune modulation with our retrospective data due to uncontrolled biases and the absence of a control group. Nevertheless, there is indirect evidence for the effects of CRRT on inflammatory immune responses. Murugan et al. reported that intensive RRT significantly lowered plasma IL-6, MIF, and TNFR-I concentrations in patients with initially higher biomarker concentrations (10). A recent study in critically ill patients found that hemodiafiltration resulted in a greater reduction in NLR after the first session than that by hemodialysis, suggesting an immunomodulatory effect of convective therapy (38). However, regardless of the immunomodulatory effects of RRT, monitoring changes in NLR after CRRT initiation may help predict patient outcome, evaluate treatment response, and make follow-up decisions.
Our study has several strengths. First, to the best of our knowledge, we first evaluated the prognostic value of NLR specifically in AKI patients requiring RRT, which is the subgroup with the highest risk of AKI. To date, there are no validated or accurate risk prediction tools for this patient group (39). Second, in contrast to previous studies, we focused on temporal changes in NLR during the initial phase of CRRT and demonstrated their association with adverse outcomes. Third, our study was based on data collected from a relatively large multicenter cohort. However, our study had some limitations. We analyzed retrospective data; thus, prospective trials are required to confirm our findings. This study was based on the Korean population, which may not be generalizable to all patients undergoing CRRT. In the main analysis, patients who died before day 5 were excluded due to missing NLR, which might also have introduced biases. In addition, NLR is not a disease-specific marker and could be affected by various factors such as age, sex, and other comorbidities (31).
In conclusion, we demonstrated that temporal changes in NLR were independently associated with 30-day mortality in AKI patients receiving CRRT. We identified significantly different dynamic natures in neutrophil and lymphocyte counts between survivors and non-survivors. Our results provide evidence for the predictive role of NLR changes during the initial phase of CRRT on mortality and highlight the importance of continuous monitoring of the NLR.
Data availability statement
The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author/s.
Ethics statement
The studies involving human participants were reviewed and approved by Institutional Review Boards of Dongguk University Ilsan Hospital (DUIH 2022-06-019-002), Seoul National University Hospital (H-2212-142-1389), Kyungpook National University Chilgok Hospital (KNUCH 2022-09-020), Eunpyeong St. Mary’s Hospital (PC21RIDI0111), and Inha University Hospital (2022-08-046). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
Author contributions
HLK and KK drafted the manuscript. JJ performed the statistical analysis. JL, J-HL, DI, YK, JHP, WP, KMK, SL, SWL, SS, DK, SH, CB, HK, and JYP contributed to data collection, curation, and interpretation. TB and KK contributed to conception and design of the study and supervised the work. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by INHA UNIVERSITY Research Grant and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2021R1I1A3052012).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1162381/full#supplementary-material
References
1. Mehta, RL, Cerdá, J, Burdmann, EA, Tonelli, M, García-García, G, Jha, V, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. (2015) 385:2616–43. doi: 10.1016/S0140-6736(15)60126-X
2. Chawla, LS, Amdur, RL, Shaw, AD, Faselis, C, Palant, CE, and Kimmel, PL. Association between Aki and long-term renal and cardiovascular outcomes in United States veterans. Clin J Am Soc Nephrol. (2014) 9:448–56. doi: 10.2215/CJN.02440213
3. Hsu, CY, and Liu, KD. Cardiovascular events after Aki: a new dimension. J Am Soc Nephrol. (2014) 25:425–7. doi: 10.1681/ASN.2013121276
4. Susantitaphong, P, Cruz, DN, Cerda, J, Abulfaraj, M, Alqahtani, F, Koulouridis, I, et al. World incidence of Aki: a meta-analysis. Clin J Am Soc Nephrol. (2013) 8:1482–93. doi: 10.2215/CJN.00710113
5. Uchino, S, Kellum, JA, Bellomo, R, Doig, GS, Morimatsu, H, Morgera, S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. (2005) 294:813–8. doi: 10.1001/jama.294.7.813
6. Metnitz, PG, Krenn, CG, Steltzer, H, Lang, T, Ploder, J, Lenz, K, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. (2002) 30:2051–8. doi: 10.1097/00003246-200209000-00016
7. Hoste, EA, Bagshaw, SM, Bellomo, R, Cely, CM, Colman, R, Cruz, DN, et al. Epidemiology of acute kidney injury in critically ill patients: the multinational Aki-epi study. Intensive Care Med. (2015) 41:1411–23. doi: 10.1007/s00134-015-3934-7
8. STARRT-AKI Investigators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group; United Kingdom Critical Care Research Group; Canadian Nephrology Trials Network; Irish Critical Care Trials Group Bagshaw, SM, Wald, R, NKJ, A, Bellomo, R, da Costa, BR, et al. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med. (2020) 383:240–51. doi: 10.1056/NEJMoa2000741,
9. Barbar, SD, Clere-Jehl, R, Bourredjem, A, Hernu, R, Montini, F, Bruyere, R, et al. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med. (2018) 379:1431–42. doi: 10.1056/NEJMoa1803213
10. Murugan, R, Wen, X, Keener, C, Pike, F, Palevsky, PM, Unruh, M, et al. Associations between intensity of Rrt, inflammatory mediators, and outcomes. Clin J Am Soc Nephrol. (2015) 10:926–33. doi: 10.2215/CJN.04560514
11. Koyner, JL, Shaw, AD, Chawla, LS, Hoste, EA, Bihorac, A, Kashani, K, et al. Tissue inhibitor Metalloproteinase-2 (Timp-2)·Igf-binding Protein-7 (Igfbp7) levels are associated with adverse long-term outcomes in patients with Aki. J Am Soc Nephrol. (2015) 26:1747–54. doi: 10.1681/ASN.2014060556
12. Azab, B, Zaher, M, Weiserbs, KF, Torbey, E, Lacossiere, K, Gaddam, S, et al. Usefulness of neutrophil to lymphocyte ratio in predicting short- and long-term mortality after non-St-elevation myocardial infarction. Am J Cardiol. (2010) 106:470–6. doi: 10.1016/j.amjcard.2010.03.062
13. Dentali, F, Nigro, O, Squizzato, A, Gianni, M, Zuretti, F, Grandi, AM, et al. Impact of neutrophils to lymphocytes ratio on major clinical outcomes in patients with acute coronary syndromes: a systematic review and meta-analysis of the literature. Int J Cardiol. (2018) 266:31–7. doi: 10.1016/j.ijcard.2018.02.116
14. Russell, CD, Parajuli, A, Gale, HJ, Bulteel, NS, Schuetz, P, de Jager, CPC, et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: a systematic review and meta-analysis. J Infect. (2019) 78:339–48. doi: 10.1016/j.jinf.2019.02.006
15. Chua, W, Charles, KA, Baracos, VE, and Clarke, SJ. Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer. (2011) 104:1288–95. doi: 10.1038/bjc.2011.100
16. Templeton, AJ, McNamara, MG, Seruga, B, Vera-Badillo, FE, Aneja, P, Ocana, A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. (2014) 106:dju124. doi: 10.1093/jnci/dju124
17. Ysebaert, DK, De Greef, KE, Vercauteren, SR, Ghielli, M, Verpooten, GA, Eyskens, EJ, et al. Identification and kinetics of leukocytes after severe Ischaemia/reperfusion renal injury. Nephrol Dial Transplant. (2000) 15:1562–74. doi: 10.1093/ndt/15.10.1562
18. Rabb, H, Daniels, F, O’Donnell, M, Haq, M, Saba, SR, Keane, W, et al. Pathophysiological role of T lymphocytes in renal ischemia-reperfusion injury in mice. Am J Physiol Renal Physiol. (2000) 279:F525–31. doi: 10.1152/ajprenal.2000.279.3.F525
19. Chen, D, Xiao, D, Guo, J, Chahan, B, and Wang, Z. Neutrophil-lymphocyte count ratio as a diagnostic marker for acute kidney injury: a systematic review and meta-analysis. Clin Exp Nephrol. (2020) 24:126–35. doi: 10.1007/s10157-019-01800-y
20. Bu, X, Zhang, L, Chen, P, and Wu, X. Relation of neutrophil-to-lymphocyte ratio to acute kidney injury in patients with sepsis and septic shock: a retrospective study. Int Immunopharmacol. (2019) 70:372–7. doi: 10.1016/j.intimp.2019.02.043
21. Abu Alfeilat, M, Slotki, I, and Shavit, L. Single emergency room measurement of neutrophil/lymphocyte ratio for early detection of acute kidney injury (AKI). Intern Emerg Med. (2018) 13:717–25. doi: 10.1007/s11739-017-1715-8
22. Chen, JJ, Kuo, G, Fan, PC, Lee, TH, Yen, CL, Lee, CC, et al. Neutrophil-to-lymphocyte ratio is a marker for acute kidney injury progression and mortality in critically ill populations: a population-based, multi-institutional study. J Nephrol. (2022) 35:911–20. doi: 10.1007/s40620-021-01162-3
23. Zhu, J, Zeng, C, Zhang, L, Shu, S, Liu, Y, Chen, G, et al. Red blood cell distribution width and neutrophil-to-lymphocyte ratio in predicting adverse outcomes of acute kidney injury in hospitalized patients. Kidney Dis (Basel). (2020) 6:371–81. doi: 10.1159/000507859
24. Knaus, WA, Draper, EA, Wagner, DP, and Zimmerman, JE. Apache ii: a severity of disease classification system. Crit Care Med. (1985) 13:818–29. doi: 10.1097/00003246-198510000-00009
25. Vincent, JL, Moreno, R, Takala, J, Willatts, S, De Mendonca, A, Bruining, H, et al. The Sofa (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine. Intensive Care Med. (1996) 22:707–10. doi: 10.1007/BF01709751
26. Zahorec, R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy. (2021) 122:474–88. doi: 10.4149/BLL_2021_078
27. Hwang, S, Park, H, Kim, Y, Kang, D, Ku, HS, Cho, J, et al. Changes in acute kidney injury epidemiology in critically ill patients: a population-based cohort study in Korea. Ann Intensive Care. (2019) 9:65. doi: 10.1186/s13613-019-0534-7
28. Zuk, A, and Bonventre, JV. Acute kidney injury. Annu Rev Med. (2016) 67:293–307. doi: 10.1146/annurev-med-050214-013407
29. Kuwabara, S, Goggins, E, and Okusa, MD. The pathophysiology of sepsis-associated AKI. Clin J Am Soc Nephrol. (2022) 17:1050–69. doi: 10.2215/CJN.00850122
30. Fan, LL, Wang, YJ, Nan, CJ, Chen, YH, and Su, HX. Neutrophil-lymphocyte ratio is associated with all-cause mortality among critically ill patients with acute kidney injury. Clin Chim Acta. (2019) 490:207–13. doi: 10.1016/j.cca.2018.09.014
31. Buonacera, A, Stancanelli, B, Colaci, M, and Malatino, L. Neutrophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci. (2022) 23:3636. doi: 10.3390/ijms23073636
32. Riche, F, Gayat, E, Barthelemy, R, Le Dorze, M, Mateo, J, and Payen, D. Reversal of neutrophil-to-lymphocyte count ratio in early versus late death from septic shock. Crit Care. (2015) 19:439. doi: 10.1186/s13054-015-1144-x
33. Lee, H, Kim, I, Kang, BH, and Um, SJ. Prognostic value of serial neutrophil-to-lymphocyte ratio measurements in hospitalized community-acquired pneumonia. PLoS One. (2021) 16:e0250067. doi: 10.1371/journal.pone.0250067
34. Brown, KA, Brain, SD, Pearson, JD, Edgeworth, JD, Lewis, SM, and Treacher, DF. Neutrophils in development of multiple organ failure in sepsis. Lancet. (2006) 368:157–69. doi: 10.1016/S0140-6736(06)69005-3
35. Le Tulzo, Y, Pangault, C, Gacouin, A, Guilloux, V, Tribut, O, Amiot, L, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock. (2002) 18:487–94. doi: 10.1097/00024382-200212000-00001
36. Drewry, AM, Samra, N, Skrupky, LP, Fuller, BM, Compton, SM, and Hotchkiss, RS. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock. (2014) 42:383–91. doi: 10.1097/SHK.0000000000000234
37. Inoue, S, Suzuki-Utsunomiya, K, Okada, Y, Taira, T, Iida, Y, Miura, N, et al. Reduction of immunocompetent T cells followed by prolonged lymphopenia in severe sepsis in the elderly. Crit Care Med. (2013) 41:810–9. doi: 10.1097/CCM.0b013e318274645f
38. Piotte, J, Louis, F, Buyansky, D, Mereniuk, E, Levesque, R, Wald, R, et al. Online Hemodiafiltration compared to conventional hemodialysis in critically ill patients. Kidney Int Rep. (2022) 7:2376–87. doi: 10.1016/j.ekir.2022.08.007
Keywords: acute kidney injury, continuous renal replacement therapy, neutrophil-to-lymphocyte ratio, inflammation, biomarker
Citation: Ko HL, Jung J, Lee J, Lim J-H, Im DW, Kim YC, Paek JH, Park WY, Kim KM, Lee S, Lee SW, Shin SJ, Kim DK, Han SS, Baek CH, Kim H, Park JY, Ban TH and Kim K (2023) Dynamic nature and prognostic value of the neutrophil-to-lymphocyte ratio in critically ill patients with acute kidney injury on continuous renal replacement therapy: A multicenter cohort study. Front. Med. 10:1162381. doi: 10.3389/fmed.2023.1162381
Edited by:
Rolando Claure-Del Granado, Hospital Obrero No 2 - CNS, BoliviaReviewed by:
Hyung Woo Kim, Yonsei University, Republic of KoreaYue Gu, Henan Provincial People’s Hospital, China
Copyright © 2023 Ko, Jung, Lee, Lim, Im, Kim, Paek, Park, Kim, Lee, Lee, Shin, Kim, Han, Baek, Kim, Park, Ban and Kim. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Tae Hyun Ban, ZGV1eDAxMjNAY2F0aG9saWMuYWMua3I=; Kipyo Kim, a3BraWRuZXlAaW5oYS5hYy5rcg==
†These authors have contributed equally to this work and share first authorship
‡These authors have contributed equally to this work and share last authorship